October 2017 Default Cover Image
AUA’s USPSTF reform efforts continueThe AUA is continuing its efforts to aggressively come to the defense of PSA screening, a simple test that has been under siege by federal government regulators who have essentially flunked it as a routine procedure for assessing prostate health.
RT-ADT combo may boost pN1 prostate cancer survivalTreatment with radiotherapy plus androgen deprivation therapy may improve survival for select patients who are found to have pathologic node-positive prostate cancer at radical prostatectomy
Statewide tests on the role of MOC multiply
Practice ‘report card’ tracks performance
You can deliver chronic care services; here’s howSome urology practices may be contemplating delivering chronic care management services to eligible patients, and this article will answer key questions about the program and features to consider when making that decision.
Current prostate Ca guidelines miss germline variantsAdherence to current guidelines for genetic testing in men with prostate cancer would miss a sizable proportion of patients with pathogenic germline variants, according to a study presented at the American Society of Clinical Oncology annual meeting in Chicago.
Varicocele: Treatment indications and repair techniquesThis article presents an overview of the pathophysiology of varicoceles and discusses indications for treatment, two primary repair techniques, and treatment outcomes.
Immune content linked to aggressive PCa outcomesThe level of immune response in prostate cancer may predict a patient’s response to radiation therapy, risk of disease recurrence, and survival outcomes, according to results of a recent analysis of prostate tumors.
Antiandrogen’s role may extend to non-metastatic CRPCTop-line results from a large phase III trial support a potential role for enzalutamide (XTANDI) as treatment for non-metastatic castration-resistant prostate cancer.
Tech advances catalyze paradigm shifts in patient careJames M. Hotaling, MD, MS, and Steven A. Kaplan, MD, introduce their new Urology Times section "Tech Talk with Jim and Steve."
Video visits in urology: How clinicians, patients benefitAmong the many areas of telemedicine, a key opportunity exists for urologists in video visits, or “direct-to-consumer” telemedicine.
In-office blue light: Solid data, and questions"Overall, the take-home message is that [blue light cystoscopy], whether in the clinic or the OR, increases the detection of tumors," writes Jeffrey M. Holzbeierlein, MD.
Blue light cystoscopy improves bladder Ca detectionBlue light flexible cystoscopy (D-Light C PDD Flexible Videoscope System) with intravesical hexaminolevulinate HCl (HAL [Cysview]) for surveillance in the office setting significantly improved the detection of recurrent bladder tumors compared with white light cystoscopy.
Two-drug therapy for advanced UC shows superior PFSAdding ramucirumab (CYRAMZA) to standard docetaxel (Taxotere) improved progression-free survival compared with docetaxel alone in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy.
Better models needed for predicting bladder Ca recurrenceCurrent NCCN guidelines are comparable to European models for predicting nonmuscle-invasive bladder cancer recurrence and progression. But better models are needed, according to a recent study.
New Products: FDA approves treatment for complicated UTIOther products and services discussed in this round-up include a biosimilar for cancer, an American College of Surgeons manual on quality initiatives, a kidney cancer microsite, and more.
[Quiz]: Defect observed during RARPDuring a robot-assisted laparoscopic radical prostatectomy case, you notice a large defect medial to the inferior epigastric artery on the right side after taking down the bladder. Similar defect is noted on the left side.
Urologists illustrate key steps in management of duct obstruction
What are you doing to work smarter, rather than harder?“We’re trying to use our mid-level providers more frequently. Basically, we let them see our post-ops and follow-ups, so we can see more patients and become more productive," one urologist says.
Stress is part of life, and urology nurses are no exceptionSUNA President Gwendolyn Hooper, PhD, APRN, asked a few colleagues to share their urology nursing stressors.
[Video] Prescription for financial health: Tips for early-stage physicians (part 1 of 4)In this video, Jeff Witz, CFP, outlines the common characteristics found in financially successful physicians and shares basic financial concepts.
[Video] Prescription for financial health: Risk management (part 2 of 4)In this video, Jeff Witz, CFP, discusses Economic Life Value as well as life and disability insurance.
[Video] Prescription for financial health: Accumulation/investments (part 3 of 4)In this video, Jeff Witz, CFP, explains "loanership" and "ownership" investment assets and shares the top five reasons for investment loss.
[Video] Prescription for financial health: Asset protection (part 4 of 4)In this video, Jeff Witz, CFP, outlines common asset protection strategies and discusses estate taxes.
Robotic vs. open RP: Better EF recovery seen with robotRobot-assisted radical prostatectomy was associated with earlier and increased rate of recovery of erectile function when compared to radical retropubic prostatectomy and a slightly higher but acceptable rate of positive surgical margins, according to a study published online in European Urology (Sept. 4, 2017).
How do active and passive fund management differ?
Single-use scope yields 45-min average surgery timeFlexible ureteroscopy using a digital single-use flexible ureteroscope known as PUSEN achieves stone-free rates on par with reusable flexible ureteroscopes, with a total surgery time averaging 45 minutes.
Single-use ureteroscope shows efficacy for routine URSA new single-use digital flexible ureteroscope (LithoVue) compares favorably in performance to reusable scopes, at least for routine urteroscopy, with a possible advantage of being more economical.
SUI: Phase III data offer lessons for trials evaluating cell therapyResults of one of the first randomized controlled trials evaluating cell therapy for women with stress urinary incontinence (SUI) has helped to identify clinically meaningful efficacy endpoints to refine patient selection criteria for current and future studies, according to investigator Melissa R. Kaufman, MD, PhD.
Bother, symptom severity often poorly correlated in LUTSThe correlation between patient-reported bother and symptom severity is inexact, according to conclusions of a recent retrospective multicenter study of nearly 1,200 patients referred for lower urinary tract symptoms.